GlassScriptPhysician profile
Alexis L Coleman
NPI 1003418302
$1,822.81
in general payments reported to CMS, 2019-2025
10 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $740 · 2022: $458 · 2023: $35.00 · 2024: $83.67 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Travel and Lodging: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.81 |
| Travel and Lodging | $151.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.81 | 2021-2022 | |
| Intuitive Surgical, INC. | $412.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $377.08 | 2021-2025 | Nucala |
| Amgen INC. | $258.65 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.57 | 2025 | Lifevest |
| Davol INC. | $35.00 | 2023 | Phasix Mesh |
| Integra Lifesciences Corporation | $23.31 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Solventum Corporation | $22.30 | 2024 | V.A.C.Ulta |
| Haemonetics Corporation | $21.83 | 2024 | Teg6s Hemostasis System |
| Genzyme Corporation | $15.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.